REDOXTHERAPIES
RedoxTherapies is a privately held company based on the pioneering adenosine research of founder Michail Sitkovsky, Ph.D. The goal of Redox is to utilize A2 adenosine antagonists to re-activate the otherwise inhibited tumor-reactive T cells, which remain inhibited even after blockade of immunological checkpoint inhibitors. Redox has compiled key assets in this space, including an exclusive license to vipadenant, a potent and selective A2a adenosine receptor antagonist, and intellectual property covering the combination of adenosine antagonists with immuno-modulatory agents.
REDOXTHERAPIES
Industry:
Health Care Pharmaceutical
Founded:
2006-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Status:
Active
Contact:
(617)742-3055
Similar Organizations
Superlative Biosciences
We provide superlative biosciences services.
Unique Pharmaceuticals
Unique Pharmaceuticals provides sterile and non-sterile outsourcing services.
More informations about "RedoxTherapies"
RedoxTherapies - Crunchbase Company Profile & Funding
RedoxTherapies is a privately held company based on the pioneering adenosine research of founder Michail Sitkovsky, Ph.D. The goal of Redox is to utilize A2 adenosine antagonists to re-activate the otherwise inhibited tumor-reactive T cells, which remain inhibited even after …See details»
Juno Therapeutics acquires RedoxTherapies - 2016-07-14
Jul 14, 2016 · Acquiring Organization: Juno Therapeutics Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer. Announced DateSee details»
The $10 million molecule: Juno Therapeutics’ …
Jul 15, 2016 · Seattle-based Juno Therapeutics has acquired RedoxTherapies for $10 million, to secure exclusive rights to a molecule that may provide a new …See details»
RedoxTherapies - Products, Competitors, Financials, Employees ...
RedoxTherapies is a company based on the pioneering adenosine research of founder Michail Sitkovsky, Ph.D. The goal of Redox is to utilize A2 adenosine antagonists to re-activate the …See details»
Juno acquires RedoxTherapies - Chemical
Jul 25, 2016 · Juno Therapeutics has acquired RedoxTherapies for $10 million in cash and potential milestone payments. With the deal comes vipadenant, a …See details»
Redoxtherapies, Inc. Company Profile | Boston, MA | Competitors ...
Find company research, competitor information, contact details & financial data for Redoxtherapies, Inc. of Boston, MA. Get the latest business insights from Dun & Bradstreet.See details»
Juno Buys RedoxTherapies for $10M+ - genengnews.com
Jul 15, 2016 · Juno Therapeutics has acquired RedoxTherapies for $10 million upfront-plus, giving the cancer immunotherapy developer a small molecule adenosine A2a receptor …See details»
RedoxTherapies Acquired by Juno Therapeutics for $10M+
Jul 19, 2016 · Juno Therapeutics is building a fully integrated biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer.See details»
Redox therapy - Wikipedia
Redox therapy is an experimental therapy [1][2] that aims to effect an outcome by modifying the levels of pro-oxidant and antioxidant agents in cells. [3] . The term "redox" is a contraction of …See details»
Defining roles of specific reactive oxygen species (ROS) in cell ...
Feb 21, 2022 · Consider redox interactions between organelles (for example, mitochondria, peroxisomes, endoplasmic reticulum, nucleus). Explore patterns of oxidative post-translational …See details»
Redox‐based therapeutics in neurodegenerative disease - PMC
In this review, we focus on the potential for developing therapeutic agents that promote the availability of thiol redox antioxidants or boost the antioxidant capacity of cells via stimulation …See details»
Potential of redox therapies in neurodegenerative disorders
Mar 1, 2017 · Redox therapy should not be applied uniformly, and must be develop to target specific mechanisms. This review focus on the main antitoxidative therapies that are used in …See details»
Targeting oxidative stress in disease: promise and limitations of ...
Jun 30, 2021 · Here, we review the relationships between oxidative stress, redox signalling and disease, the mechanisms through which oxidative stress can contribute to pathology, how …See details»
Understanding mechanisms of antioxidant action in health and …
Sep 15, 2023 · ROS are counterbalanced by an antioxidant defence network, which functions to modulate ROS levels to allow their physiological roles whilst minimizing the oxidative damage …See details»
Pharmacology and Clinical Drug Candidates in Redox Medicine
We here review the current status and outlook of the most advanced areas in the field of translational redox medicine by focusing on drugs in four categories: The main, if not only, …See details»
Redox regulation and its emerging roles in cancer treatment
Jan 15, 2023 · In this review, we provide a detailed description and analysis of the latest advances in redox regulation–based nanotherapies, focusing on the basic material chemistry …See details»
Potential of redox therapies in neurodegenerative disorders
The World Health Organization (WHO) estimates that, by 2040, neurodegenerative diseases will be the main cause of death in industrialized countries ahead of the cancers. The redox …See details»
Fundamentals of redox regulation in biology - Nature
Apr 30, 2024 · Here, we discuss new insights into the dynamic maintenance of redox homeostasis (that is, redox homeodynamics) and the principles underlying biological redox organization, …See details»
Systems redox biology in health and disease - PMC
Understanding how the multi-layered biological stress responses become integrated across and between different levels of organization within an organism can provide a different perspective …See details»
Fundamentals of redox regulation in biology - Nature
Here, we discuss new insights into the dynamic maintenance of redox homeostasis (that is, redox homeodynamics) and the principles underlying biological redox organization, termed the …See details»